Technical indicators flash caution. As of July 30, the stock traded at $84.82, well above its 20-day ($77.87), 50-day ($73.95), and 200-day ($67.45) moving averages. RSI sat at 72.87, Stochastic RSI at 88.22, and CCI at 195.16 — all signaling overbought conditions. The coming week's forecast range is $82.68 to $85.12, with breakout potential toward the 52-week high of $87.32 if resistance clears.
Recent earnings underscore steady but unspectacular execution. Q2 fiscal 2026 adjusted EPS of $1.29 beat consensus of $1.2846 by 0.42%, yet the stock dipped 0.7% on the news. Revenue for the quarter was not disclosed in the available reports.
Institutional interest remains elevated: the Healthcare of Ontario Pension Plan Trust Fund acquired 114,277 shares in Q1 2026, valued at roughly $6.4 million. Hedge funds and institutions own 99.67% of outstanding shares.
Over the past decade, HAE has compounded at a 10.17% annualized total return (dividends reinvested), turning $10,000 into $26,341. The current rally adds a strong recent chapter to that long-term record, but the valuation re-rating and overbought technicals raise the bar for the next leg higher.
What to Watch
The question now is whether Plasma momentum and Hospital segment innovation can sustain earnings growth sufficient to justify the expanded multiple, or whether the fair-value thesis has largely played out?
Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6
